Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

LA JOLLA, Calif., March 26 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the fourth quarter and year ended December 31, 2007. For the full year 2007, the Company posted revenue of $9.9 million and a net loss of $23.4 million. Cash and cash equivalents totaled $32.5 million at December 31, 2007.

"We made meaningful progress in our three clinical development programs in 2007," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Particularly noteworthy was the successful completion of our Phase IIb clinical trial that demonstrated that tezampanel relieved migraine pain at a dose that is safe and well-tolerated. We look forward to an End of Phase II meeting with the FDA to discuss advancing tezampanel into Phase III. In 2008, we are continuing to build a strong clinical platform for our other product candidates: NGX426, our oral glutamate receptor antagonist, and NGX267, our lead M1 agonist, that is currently in a Phase II trial for xerostomia secondary to Sjogren's syndrome."

2007 Highlights:

-- Tezampanel met the primary endpoint at the 40 mg dose in a 306-patient,

Phase IIb clinical trial for the treatment of a single, acute migraine

attack. This is the sixth Phase II trial in which tezampanel has been

shown to have analgesic activity and the second placebo-controlled

trial to establish efficacy for tezampanel as a treatment for acute

migraine. TorreyPines intends to hold an End of Phase II meeting with

the U.S. Food and Drug Administration (FDA) in the second half of 2008

to discuss the scope of a Phase III program with tezampanel for the

treatment o
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... LAGUNA HILLS, Calif., Sept. 4 CODA Genomics, ... Optimized DNA,Assembly) towards the manufacture of synthetic genes ... Patent and Trademark Office has,issued US Patent 7,262,031 ... (UCI) professors, Richard H. Lathrop and G. Wesley,Hatfield. ...
... Sept. 4 Volcano,Corporation (Nasdaq: VOLC ), ... (FM) products designed to enhance the diagnosis,and treatment ... that it,will be participating in the Bear Stearns ... presentation by Scott Huennekens, president and chief executive,officer, ...
... (Nasdaq: ALXN ) today announced that Dr. Leonard ... the,Bear Stearns 20th Annual Healthcare Conference in New York ... An audio webcast of Dr. Bell,s remarks will ... http://www.alexionpharm.com . An archived version of the,remarks will also ...
Cached Biology Technology:CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent 2Volcano Corporation Presentation at Bear Stearns Conference to be Webcast 2
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... issue of Nature Methods Shows Application of Bioinformatics ... ... GENEVA, Switzerland, Aug. 21 Researchers at Selexis SA,and ... novel,high-performance Genetic Elements also known as matrix attachment regions,(or ...
... know that not all plants from the same species ... that not only prevent the exchange of genes between ... a species), but also between varieties of one and ... central importance if one wants to understand the origin ...
... Europe, which many archaeologists believed to be descended from ... East by Stone Age farmers, new research suggests. ... at Durham University, which is published today in the ... USA, analysed mitochondrial DNA from ancient and modern pig ...
Cached Biology News:Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines 2How the plant immune system can drive the formation of new species 2How the plant immune system can drive the formation of new species 3Pig study sheds new light on the colonisation of Europe by early farmers 2
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... A number of modifications of Grace's ... the late 1960's and 1970's. Many of ... Hink for the growth of cells derived ... represents the modification known as TNM-FH. The ...
... GST•Tag™ Ek Adaptor encodes a T7 promoter, ... (rbs), ATG translation initation codon and an ... has been reported to enhance the production ... its fusion partners. The GST•Tag is a ...
...
Biology Products: